Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185065 · ClinicalTrials.gov registry record · Phase 3
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
A Phase 3 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
NCT03185065: Completed Phase 3 study, sponsored by Johns Hopkins University.
NCT03185065 is a Phase 3 study that has completed, run by Johns Hopkins University. The registered enrollment target is 141 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03185065, a Phase 3 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
Study Summary
Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS defined by McDonald Criteria.
Primary Outcome
MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue.
Interventions
- DRUG Placebos
- DRUG Methylphenidate
- DRUG Modafinil
- DRUG Amantadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2019-11-21 |
| Phase | Phase 3 |
What the finished NCT03185065 record still lists
NCT03185065 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebos is the first listed.
NCT03185065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03185065 about?
NCT03185065 is a clinical study titled "Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis". Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS defined by McDonal...
What is the current status of trial NCT03185065?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2017-10-04. Estimated completion is 2019-11-21.
What interventions are being tested in trial NCT03185065?
The interventions under investigation include: Placebos (DRUG), Methylphenidate (DRUG), Modafinil (DRUG), Amantadine (DRUG).
Who is sponsoring clinical trial NCT03185065?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03185065's enrollment target sits among peer trials
141 1563rd of 2000 higher than 436 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI